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Abstract: Acrodermatitis continua of Hallopeau (ACH) is a rare, sterile pustular eruption of
one or more digits. The condition presents with tender pustules and underlying erythema on
the tip of a digit, more frequently arising on a finger than a toe. As far as classification, ACH
is considered a localized form of pustular psoriasis. The eruption typically occurs after local
trauma or infection, but such a history is not always present and various other etiologies have
been described including infectious, neural, inflammatory, and genetic causes. The natural
progression of ACH is chronic and progressive, often resulting in irreversible complications
such as onychodystrophy that can result in anonychia, as well as osteitis that can result in
osteolysis of the distal phalanges. Because of the rarity of ACH, there have been no
randomized controlled studies to evaluate therapies, resulting in an absence of standardized
treatment guidelines. In clinical practice, a wide variety of treatments have been attempted,
with outcomes ranging from recalcitrance to complete resolution. In recent years, the
introduction of biologics has provided a new class of therapy that has revolutionized the
treatment of ACH. Specifically, rapid and sustained responses have been reported with the
use of anti-tumor necrosis factor agents like infliximab, adalimumab, and etanercept; IL-17
inhibitors like secukinumab; IL-12/23 inhibitors like ustekinumab; and IL-1 inhibitors like
anakinra. Nevertheless, there remains a considerable need for more research into treatment
for the benefit of individual patients with ACH as well as for the clinical knowledge gained
by such efforts. The purpose of this review is to provide a comprehensive overview of the
key features of ACH as well as a discussion of clinical management strategies for this unique
and debilitating condition.
Keywords: acrodermatitis continua of Hallopeau, psoriasis, pustular psoriasis, generalized
pustular psoriasis, palmoplantar pustulosis
Introduction
Acrodermatitis continua of Hallopeau (ACH) is a rare, chronic, sterile pustular
eruption of one or more digits. This entity has also been called pustular acroder-
matitis, acrodermatitis continua suppurativa, dermatitis perstans, acropustulosis,
acrodermatitis perstans, and dermatitis repens.1–4
ACH presents with tender, sterile pustules and underlying erythema on the tip of
a digit, more frequently arising on a finger than a toe.1,5 The eruption typically
occurs after local trauma or infection,6–8 however, such a history is not always
present4 and neural and inflammatory etiologies have also been described.5 ACH
always involves the nail apparatus; if there is no nail involvement, then alternative
diagnoses such as palmoplantar pustulosis (PPP) should be considered.6 Over time,
ACH becomes chronic and can exhibit proximal progression, extending to the
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dorsal aspect of the hand or the foot.7 Without successful
treatment, ACH can lead to several complications, includ-
ing onychodystrophy that can result in anonychia as well
as osteitis that can result in osteolysis of the distal
phalanges.4,5,7–9 In these ways, ACH can cause profound
disability and have a tremendously negative impact on
quality of life in these patients.
As far as classification, ACH is considered a localized
form of pustular psoriasis.2,5,10 It appears to be most
common in middle-aged females, but due to the overall
rarity of ACH, epidemiological information is limited to
anecdotal case reports.6,9,11,12 Relatedly, there are no stan-
dardized guidelines for treating ACH, but rather various
case reports with a wide range of therapeutic approaches
and outcomes.
The purpose of this review is to provide a comprehen-
sive overview of the key features of ACH as well as a
discussion of clinical management strategies for this
unique and debilitating condition.
Methods
This review is based on a literature search in MEDLINE
and Embase databases. The search was performed in
February 2019. The following keywords were used:
“Acrodermatitis continua of hallopeau,” “acrodermatitis
continua,” “dermatitis repens,” “acrodermatitis perstans,”
“Hallopeau*,” AND “psoria*.” Only articles written in
English were included, and no restrictions were set on
study type. No institutional review board approval was
required for this review article.
Results
Pathophysiological mechanisms
As mentioned, various etiologies have been described for
ACH, including traumatic, infectious, neural, and inflam-
matory causes.5 In the majority of case reports, the patient
recalls a minor trauma or infection preceding symptoms in
the same location; however, many patients deny such pre-
cipitating factors.9,13
In recent years, several studies have suggested genetic
causes of ACH. For example, two papers published in
2011 reported mutations in the IL36RN gene among
patients with pustular psoriasis.14,15 IL36RN is amply
expressed in the skin and belongs to the IL-1 cytokine
family that is involved in the innate immune system.
Several IL36 isoforms (IL-36α, IL-36β, and IL-36γ)
induce cytokines that contribute to a pro-inflammatory
cascade by binding to the IL-1 RL2 receptor and initiating
the recruitment and localization of T cells, neutrophils, and
dendritic cells to the skin.10,14–16 The IL36RN gene
encodes the IL36 receptor agonist (IL-36Ra), which nor-
mally acts to inhibit such pro-inflammatory signaling.
Mutations in IL36RN can thereby lead to unregulated
secretion of inflammatory cytokines,14,15,17 and such muta-
tions have been found in several cases of familial general-
ized pustular psoriasis (GPP). This inherited form is now
known as DITRA, ie, “Deficiency of Interleukin-Thirty six
Receptor Antagonist.” The authors of these papers suggest
that such genetic mutations may also be related to other
forms of pustular psoriasis such as ACH.10,15,18
In 2013, a team of researchers identified a homozygous
missense mutation in IL36RN in a male patient with ACH
as well as his female sibling with GPP, confirming that
these two diseases are likely related.10 Genetic linkages
are also seen within single patients; for example, a 2019
study identified nine patients with both ACH and GPP and
four patients with both ACH and PPP.19 Such reports are
further supported by additional studies confirming the
genotype–phenotype correlation between IL36RN muta-
tions and GPP, PPP, and ACH.17,20–22 As of May 2017, a
total of 16 IL36RN mutations had been discovered, and
these disease alleles are now believed to account for
approximately 20% of ACH cases.6
While IL36RN mutations are the most frequent genetic
abnormality in pustular forms of psoriasis,19 CARD14 and
AP1S3 have also been identified as causative or suscept-
ibility genes in ACH.20,23,24 First, CARD14 encodes pro-
teins produced by keratinocytes, and gain-of-function
mutations lead to increased activation of nuclear factor-
kappa B signaling and production of tumor necrosis fac-
tor-alpha (TNF-α),8 which has been identified in association
with ACH as well as GPP, PPP, and psoriasis vulgaris
(PV).25–28 Second, AP1S3 plays a role in vesicular traffick-
ing within keratinocytes, and loss-of-function mutations
cause abnormal autophagy, increased activation of TNF-α,
and overexpression IL36α.8 Variants in AP1S3 have been
described to contribute to ACH as well as GPP and
PPP.23,29 Interestingly, preliminary research suggests that
patients with ACH are more likely to carry two distinct
mutations (ie, IL36RN and AP1S3 or IL36RN and
CARD14) than patients affected by other forms of pustular
psoriasis,19,26,29,30 but there is a need for more investigation
in this area.
In summary, current evidence demonstrates that ACH
is associated with a variety of genetic mutations in the
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genes IL36RN, CARD14, and AP1S3. Mutations in these
same genes are associated with phenotypically related
pustular skin conditions such as GPP and PPP.
Clinical features
Symptoms of ACH typically begin with the tip of one digit
turning erythematous and developing painful pustules that
migrate under the nail bed and matrix, leading to
onychodystrophy.1,3 In the acute phase, the pustules rup-
ture and coalesce to form “a lake of pus that carries the
nail away,” as this condition is classically described.1,5
The resulting anonychia leaves behind an erythematous,
shiny, and smooth distal digit where pustules often
reform.18,31 As the disease progresses, the affected digits
can become hyperkeratotic with psoriasiform scaling and
continuing pustulation.5 In longstanding cases, ACH can
progress to involve additional digits or extend proximally
to the dorsal hand or foot; however, the disease typically
remains localized to the digit(s) for months or years before
such proximal progression.5,32 These clinical findings are
seen in Figure 1, which illustrate a classic case of
chronic ACH.
Rarely, the disease can cause osteitis of the underlying
phalanges, resulting in osteolysis in severe cases.3,5,31,33,34
Very rarely, ACH has been reported to result in acquired
syndactyly, likely due to ACH lesions causing loss of
interdigital epidermis and allowing for healing with fusion
of adjacent tissues.4,35
There are several aspects of ACH’s clinical features
that support its classification as a variant of pustular
psoriasis. First, the previously described genetic muta-
tions common to patients with ACH, GPP, and PPP
suggest these conditions are on the same autoimmune
inflammatory spectrum. Second, several authors have
reported the development of joint pain and arthritis in
patients with ACH.3,33,34 Soft tissue and bone involve-
ment, often revealed on X-ray imaging, further supports
the association of ACH with psoriasis and associated
arthritis. Third, there have been instances of geographic
tongue in patients with ACH, which is a finding consis-
tent with other forms of pustular psoriasis and other
inflammatory conditions.36 Lastly, ACH can progress to
GPP, particularly the life-threatening von Zumbusch
type.4,5,32,37,38 Such patterns of progression highlight the
critical importance of recognizing ACH as a localized
form of pustular psoriasis that is unique, can rapidly
evolve, and must be aggressively treated to prevent
complications.
Differential diagnosis
ACH is commonly misdiagnosed. Based on clinical pre-
sentation, its purulence can imitate bacterial, fungal, or
viral paronychia.11 Depending on the patient’s age and
comorbidities, secondarily infected contact dermatitis,
dyshidrotic eczema, or a paraneoplastic process are rea-
sonable possibilities.4 Furthermore, other infections of the
digits such as herpetic whitlow can present with vesiculo-
pustules while dermatophytosis can present with scaly
erythema, both resembling ACH. Autoimmune conditions
such as pemphigus vulgaris can imitate ACH by present-
ing with inflammation and erosions of the digits. In a
review by Seghal et al, the authors warn that late clinical
manifestations of ACH may necessitate evaluations for a
number of conditions including squamous cell carcinoma,
melanoma, pyogenic granuloma, Reiter’s disease,
Figure 1 Right foot of a 64-year-old patient who first presented with asymmetric dactylitis characterized by erythema and tenderness of the first, third, and fourth distal
interphalangeal joints with associated nail deformities. Written informed consent was obtained to take and publish the photographs above. Patient reported a history of
possible osteomyelitis diagnosed by primary care provider, but this diagnosis was not supported by imaging, and symptoms progressed despite antibiotic treatment. Initially
treated with topical steroids, resulting in preliminary improvement of skin changes. Approximately, 6 months after skin changes began, patient was found to have the findings
documented in these figures. The clinical history and presentation of pustules, scale, erythema, and nail dystrophy of the first, third, and fourth digits were consistent with
chronic Acrodermatitis continua of Hallopeau.
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subungual fibroma, glomus tumor, blastomycosis, and
onychomycosis.5
The most important condition to compare and contrast
with ACH is PPP. Fortunately, several key features help
distinguish these related conditions. First, ACH often fol-
lows trauma, as previously described, whereas PPP rarely
involves a history of injury. Second, suppurative nail
involvement is an early and defining feature of ACH
whereas PPP does not always affect the nails and is
usually non-suppurative.6 Third, ACH most commonly
remains unilateral and localized to a limited number of
digits and with an irregular distribution for many years,
while PPP is most commonly bilateral and symmetrical.2
Lastly, features such as soft tissue sclerosis and osteolysis
as described in ACH are not reported in PPP.39
Overall, the similarities between ACH with many other
conditions, especially PPP, necessitate a careful considera-
tion of a broad differential diagnosis and a thorough clin-
ical workup, as appropriate.
Histopathology
While the diagnosis of ACH is primarily clinical, based on
the history and clinical findings described, skin and nail
biopsies with staining and cultures can be helpful to
exclude other conditions in the differential.12 ACH
appears histologically very similar to pustular psoriasis,
with subcorneal neutrophilic pustules, spongiform pus-
tules, and moderate lymphohistiocytic infiltrate.1,4,5
Chronic ACH lesions usually show severe atrophy of the
papillary dermis and thinning of the epidermis.5 The nail
matrix is always involved and typically exhibits moderate
acanthosis, lymphocytic and neutrophilic exocytosis, and
spongiosis.40 Lastly, bacterial cultures are routinely sterile
but can yield predominant growth of commensals, which
is interpreted as non-contributory to the pathogenesis of
this non-infectious inflammatory disease.6
Management
ACH is characteristically chronic and recalcitrant in nat-
ure, and spontaneous improvement has rarely been
observed.2,5,12,32 Furthermore, the condition is so rare
that there have been no controlled studies to evaluate
therapies, resulting in an absence of standardized treatment
guidelines.12 As a result, many therapeutic options have
been attempted, with equivocal results as described in case
reports.5
Historically, the most common therapies for ACH have
been similar to treatments for other forms of psoriasis,
especially PPP,1,5,12,31 including topical and oral
corticosteroids,5,41 topical vitamin D analogs,42–45 topical
fluorouracil,46,47 topical calcineurin inhibitors,48 tar,5 topi-
cal and systemic retinoids,39,49,50 cyclosporine,51–54
methotrexate,48,55,56 and phototherapy or photochemo-
therapy.5 In addition, granulocyte and monocyte adsorp-
tion apheresis has been attempted in ACH, with promising
results in a small number of patients and far fewer side
effects than some of the more traditional therapies.57–60
In most reported cases, a combination of these modal-
ities is used (ie, systemic oral medication plus a topical
applied to the affected area), with clinical responses ran-
ging from recalcitrance to complete resolution.5 Nail
lesions are typically more difficult to manage than skin,61
and recurrence is common with decrease in dosing or
cessation of treatment.5 Furthermore, the potential toxici-
ties associated with several of these systemic therapies can
prevent or limit the duration of treatment in certain indi-
viduals, especially children and elderly patients with
ACH.5,62–64
In recent years, the introduction of biologics has pro-
vided a new class of therapy that has revolutionized the
treatment of ACH.5 Specifically, rapid and sustained
responses have been reported with the use of anti-TNF
agents like infliximab,55,65,66 adalimumab,67–71 and
etanercept,72–77 IL-17 inhibitors like secukinumab,78–80
IL-12/23 inhibitors like ustekinumab,81,82 and IL-1 inhibi-
tors like anakinra.83 Furthermore, the identification of
IL36RN mutations as a genetic contributor to ACH has
informed the development of biologics that specifically
block IL-36 signaling.19 A 2017 paper described a high
affinity, anti-human IL-36 receptor antagonist antibody
that was initially tested in vitro and shown to directly
inhibit IL-36-R-mediated signaling and inflammatory
cytokine production in primary human keratinocytes and
dermal fibroblases.84 Following this work, a Phase I proof-
of-concept study among seven patients with GPP treated
with this anti-IL-36 monoclonal antibody showed signifi-
cant improvement in symptoms.85 Interestingly, the anti-
IL-36 treatment was equally effective regardless of the
absence or presence of an IL36RN mutation, suggesting
the IL-36 pathway can be pathogenic regardless of a
patient’s genetic background.8,84,85
The use of both existing and emerging biologic agents
to treat ACH, especially cases that are refractory to tradi-
tional treatments, is an area of ongoing research and devel-
opment. No single agent has yet been identified as superior
for ACH, but several have demonstrated efficacy,
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representing a promising new chapter for managing this
chronic and often debilitating disease.
Discussion
These results demonstrate that ACH is a rare condition
that is genetically and phenotypically related to other
forms of pustular psoriasis but distinct in several dimen-
sions that influence clinical outcomes. The relatively
sparse number of case reports and consequent lack of
epidemiological or controlled studies can make this con-
dition particularly difficult for clinicians to manage.
Fortunately, biologic agents offer a new treatment option
with overwhelmingly positive results, especially in recal-
citrant and refractory cases.5
Nevertheless, there remains a need for more targeted
research on the causes and management of ACH. First, the
knowledge gained by identifying genetic mutations as a
cause of ACH needs to be harnessed to develop more
targeted treatment options. For example, IL36RN muta-
tions result in defects in IL-1 signaling, as discussed.
This elucidates why agents like anakinra (an IL-1 antago-
nist) have been reported as successful in treating ACH, but
optimal treatment may require developing agents that spe-
cifically target IL-36 or common pathways between IL-1
and IL-36.8,10 As such research moves forward, it will be
critical to recruit patients with ACH who have different
genetic backgrounds to determine the efficacy of these
new agents across the spectrum of genetic profiles, includ-
ing patients with no identified mutations.
Second, genetic studies have revealed strong associa-
tions between IL36RN mutations but have also uncovered
variants in other genes among patients with ACH, such as
CARD1421 and AP1S3.20 These findings suggest a more
complicated genetic picture to this disease beyond
IL36RN, and there is a need for additional studies to
more fully characterize its genetic underpinnings.
Third and perhaps most importantly, the rarity of
ACH has thus far prevented rigorous research to estab-
lish evidence-based treatment guidelines. Given the pain
and disfigurement caused by ACH, the potential for
serious and irreversible complications, and the associa-
tion of this rare variant with life-threatening forms of
pustular psoriasis, there remains considerable need for
more research into treatment for the benefit of individual
patients with ACH as well as for the clinical knowledge
gained by such efforts.
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